CDSCO Panel approves Eli Lilly proposal to Increase patients number from India 37 to 57 for LY3871801 study

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved pharmaceutical major Eli Lilly's proposal to increase the number of patients from India from 37 to 57 for phase 2a part of the study of anti-rheumatoid drug LY3871801.

This came after Eli Lilly and Company presented an increase in the number of patients from India from 37 to 57 for phase 2a study Protocol No.: J3P-MC-FTAF8.

Rheumatoid arthritis, or RA, is an autoimmune and inflammatory disease, which means that your immune system attacks healthy cells in the body by mistake, causing inflammation (painful swelling) in the affected parts of the body. RA mainly attacks the joints, usually many joints at once.

LY3871801 is an investigational drug currently undergoing clinical trials for various purposes, including the treatment of rheumatoid arthritis.

At the recent SEC meeting for analgesic and rheumatology held on 19th March 2025, the expert panel reviewed the presentation for the increase in the number of patients from India from 37 to 57 for phase 2a study Protocol No.: J3P-MC-FTAF8.

After detailed deliberation, the committee recommended approval of an increase in the number of patients from India from 37 to 57 for phase 2a part of the study as presented by the firm.

Also Read: CDSCO Panel Approves Dr Reddy's Laboratories Protocol Amendment Proposal to study Abatacept